The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> July 18, 2012

NxStage Medical, Inc. (NXTM)

Burbank, Jeffrey H.
Jeffrey H. Burbank is the Founder, Chief Executive Officer and is a member of the board of directors at NxStage Medical, Inc. He has more than 20 years of in-depth management experience with companies developing, marketing and manufacturing products for end-stage renal disease patients. Mr. Burbank has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering and the acquisition of Medisystems. Before founding NxStage, he cofounded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and CEO, as well as Chairman of the board. Mr. Burbank gained significant renal industry experience during his nine years in the renal division at Gambro, Inc., with his last position as Director of Marketing and Advanced Technologies. During his career, Mr. Burbank has been an inventor on more than 50 U.S. patents for medical devices. He received his B.S. in industrial engineering from Lehigh University. Profile
TWST: Please begin with a background or historical sketch of NxStage Medical, enough information to put into context what you see as the business, and what you see as the company today.

Mr.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc
CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy